Bollinger Lisa 4

What Happened

• Lisa Bollinger, a director of Apogee Therapeutics, was granted a derivative award on 2026-06-09: an option representing the right to purchase 7,657 shares of Apogee common stock. The filing reports the transaction price as $0.00 and shows no immediate cash proceeds or sale — this is a grant of an equity award, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-11 (filed two days after the transaction).
• Security type: derivative (option/award) for 7,657 shares; reported price: $0.00 per share (as listed on the Form 4).
• Vesting: The option vests on the one-year anniversary of the grant date, subject to Bollinger’s continued service (per footnote).
• Shares owned after transaction: not specified in the filing.
• Filing timeliness: appears timely (filed within two business days of the reported transaction).

Context

• This transaction is a grant of an option-like award. It does not represent an immediate purchase or sale of shares and does not indicate that shares were exercised or sold at this time. Vesting conditions mean the right to buy the shares will only become effective if Bollinger remains with the company through the vesting date.